LUYE PHARMA GROUP LTD.

Insiders Luye Pharma Group Ltd.

Equities

2186

BMG570071099

Market Closed - Hong Kong S.E. Other stock markets 04:08:22 2024-04-29 am EDT			5-day change	1st Jan Change
2.75 ^HKD	+1.10%		+5.36%	-26.27%

Mar. 27	Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 07	Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Luye Pharma Group Ltd. Announces Board Changes	Dec. 06	CI
Luye Pharma Group Ltd. Appoints XIA Lian as an Independent Non-Executive Director	23-05-25	CI
Luye Pharma : Innovative Anti-Cancer Therapy Lurbinectedin to Benefit “Named Patients” in Hong Kong	23-01-09	PU
Luye Pharma Group Ltd. Appoints Sun Xin as Non-Executive Director	21-02-08	CI
Luye Pharma Group Ltd. Announces Executive Changes	20-12-01	CI
Luye Pharma Group Ltd. Announces Appointment of SONG Rui Lin as Non-Executive Director	17-03-29	CI
Luye Pharma Group Ltd. Announces Board Changes	16-06-08	CI
Luye Pharma Group Appoints Mr. YANG Rong Bing as Vice Executive Chairman of the Board	15-03-30	CI
Luye Pharma Group Ltd. Announces Cessation of Chen Wende as Chief Operating Officer, with Effect from August 15, 2012	12-07-23	CI
Luye Pharma Group Ltd. Announces Resignation of Kong Teck Chien as Non-Executive Director	12-02-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer